UroGen Pharma Reports ENVISION Trial Results Published In The February Issue Of The Journal Of Urology Highlight UGN-102 Achievement Of 82.3% Duration Of Response at 12 Months Paving The Way For The Potential First FDA-Approved Treatment For LG-IR-NMIBC I